Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BNT116 + Docetaxel |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BNT116 | BNT-116|BNT 116 | BNT116 is composed of liposomal RNAs encoding 6 tumor-associated antigens, which may potentially inhibit tumor growth (Ann Oncol (2022) 33 (suppl_7): S1095). | ||
| Docetaxel | Taxotere | RP56976 | Antimicrotubule Agent 14 | Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05142189 | Phase I | BNT116 + Carboplatin + Cemiplimab + Paclitaxel BNT116 + ONC-392 BNT116 + Cemiplimab BNT116 + Docetaxel BNT116 | Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (LuCa-MERIT-1) | Recruiting | USA | TUR | POL | HUN | GBR | ESP | DEU | AUS | 0 |